Heterozygous living donor liver transplantation for pediatric maple syrup urine disease with new compound mutation of BCKDHB gene: a case report and literature review / 器官移植

Objective To evaluate the clinical efficacy of heterozygous living donor liver transplantation for pediatric maple syrup urine disease. Methods A 3-year-old boy was admitted to the hospital on July 5, 2017 due to maple syrup urine disease for half a year. The child presented with paroxysmal dysarthria and motor dysfunction of the lower limbs under fasting status for half a year, accompanied with obvious maple syrup urine odor and slow language development. No other growth abnormality or mental defects were observed. Serum branched chain amino acid (BCAA) assay detected that the level of leucine was 684 μmol/L and 559 μmol/L for the valine. The child was diagnosed with maple syrup urine disease type b based on gene detection combined with BCAA assay. Living donor liver transplantation from his biological father was performed. Postoperatively, routine immunosuppression, anti-virus, anti-infection therapies, maintenance of fluid, electrolyte, and acid-base balance and other necessary nutritional support were given. The dose of tacrolimus was adjusted according to biochemical parameters and cytochrome P450(CYP)3A5 genotype of the recipient. Glucocorticoid administration was terminated at approximately 6 months after operation. Results The liver function of the recipient was recovered to normal range at postoperative 1 month, and basically stabilized at 3 years after surgery. The amino acid level was decreased to normal level immediately after operation, and BCAA was continually declined after normal diet for postoperative 1 month. As of the submission date, the recipient grew well in a stable condition and achieved high quality of life. Conclusions Heterozygous living donor liver transplantation is a safe and effective treatment of maple syrup urine disease, which reduces the possibility of sudden acute metabolic events, significantly improves the quality of life of the recipient and provides a novel idea for surgical treatment of maple syrup urine disease.

Aminoácidos de cadena ramificada: implicaciones en la salud / Branched chain amino acids and health implications

El consumo de proteína y especialmente aminoácidos esenciales juega un papel fundamental en la dieta, ya que suple las necesidades de nitrógeno del organismo y favorece el mantenimiento de estructuras corporales. En los últimos años, la nutrición y la tecnología de los alimentos están experimentando una profunda transformación debido al desarrollo del concepto de alimentos funcionales y nutracéuticos. Tanto las proteínas funcionales como los péptidos bioactivos están cobrando gran importancia ya que, además de su papel nutricional por ser fuente de aminoácidos, son capaces de ejercer diferentes efectos biológicos específicos sobre el sistema inmune, el sistema cardiovascular o el tracto gastrointestinal. Los aminoácidos de cadena ramificada (BCAAs denominación por las siglas en inglés) como lo son la Leucina, Isoleucina y Valina son considerados útiles para el tratamiento y predicción de algunas enfermedades, el presente artículo de revisión, se recopila información acerca de los aminoácidos de cadena ramificada y su uso positivo en el tratamiento de diferentes patologías como enfermedades neurológicas, hepáticas, cardiometabólicas, cáncer, además de su uso en deportistas. Se tuvieron en cuenta los siguientes criterios de inclusión: 1. La búsqueda se realizó en reconocidas bases de datos, 2. Se incluyeron artículos desde el 2006 a la fecha, 3. Se realizó la búsqueda con palabras como aminoácidos de cadena ramificada y efecto en diferentes patologías, con la inclusión de artículos donde se menciona el consumo humano de los mismos, se excluyeron artículos donde los aminoácidos no intervengan de manera positiva en su consumo y tratamiento de enfermedades(AU)

The consumption of protein and especially essential amino acids play a fundamental role in the diet, in order to meet the body's nitrogen needs and the maintenance of body structures. In recent years nutrition and food technology are undergoing a profound transformation due to the development of the concept of functional foods and nutraceuticals. Both functional proteins and bioactive peptides are becoming very important since, in addition to their nutritional role as a source of amino acids, they are capable of exerting different specific biological effects on the immune system, the cardiovascular system or the gastrointestinal tract. Branched-chain amino acids (BCAAs), such as Leucine, Isoleucine and Valine, are considered useful for the treatment and prediction of some diseases. This review article collects information about branched-chain amino acids. and it's positive use in the treatment of different pathologies such as neurological, liver, cardiometabolic diseases, cancer, in addition to it's use in athletes. The following inclusion criteria were taken into account: 1. The search was carried out in recognized databases, 2. Articles were included from 2006 to date, 3. The search was carried out with words such as branched-chain amino acids and effect in different pathologies, with the inclusion of articles where their human consumption is mentioned, articles were excluded where amino acids do not intervene positively in their consumption and treatment of diseases(AU)

Efeitos dos aminoácidos de cadeia ramificada na resposta inflamatória induzida por lipopolissacarídeo em macrófagos de linhagem celular RAW 264. 7 / Effects of branched-chain amino acids in the inflammatory response induced by lipopolysaccharide in a macrophage cell line RAW 264. 7

Os aminoácidos de cadeia ramificada (ACR) são considerados indispensáveis, pois não podem ser sintetizados endogenamente, sendo facilmente obtidos pela dieta. Entretanto, em determinadas condições clínicas, tanto a ingestão quando a absorção desses aminoácidos pode estar comprometida, levando ao estado hipercatabólico e prejudicando a função imune. O papel imunomodulador dos ACR tem sido relacionado com a melhora no balanço nitrogenado e o aumento da síntese e proliferação de células imunes, bem como, da síntese de mediadores inflamatórios. Entretanto, o mecanismo pelo qual os ACR exercem essas funções supracitadas ainda não é claro na literatura científica. Desta forma, esse trabalho teve como objetivo avaliar os efeitos da suplementação com ACR sobre os parâmetros inflamatórios e moleculares em macrófagos RAW 264.7 estimulados com lipopolissacarídeo (LPS). As culturas celulares foram distribuídas em cinco grupos: CTL - sem suplementação com ACR; LEU - suplementado com leucina (2 mmol/L); ISO - suplementado com isoleucina (2mmol/L); VAL - suplementado com valina (2 mmol/L) e LIV - suplementado com leucina (2 mmol/L), isoleucina (2 mmol/L) e valina (2 mmol/L). O estado inflamatório foi induzido pela adição de LPS (1 µg/mL) ao meio de cultura, seguindo quatro protocolos de tratamento: PT - pré-tratamento; TA - tratamento agudo; TC - tratamento crônico e TT - tratamento tardio. O ensaio de viabilidade celular foi realizado pelo teste MTT e a dosagem de óxido nítrico (NO) pela reação de Griess. As citocinas pró e anti-inflamatórias, e a prostaglandina E2 (PGE2) foram analisadas pelo método de ELISA. Para a avaliação dos parâmetros moleculares foi utilizado o método de western blotting. Houve aumento da viabilidade celular em todos os grupos suplementados em relação ao grupo controle no TA, no TC e no TT. Acerca da síntese de NO, a suplementação com ACR foi capaz de aumentar esse parâmetro em três dos quatro tratamentos propostos (PT, TA e TC). Em relação à síntese de citocinas pró e anti-inflamatórias, o PT e o TC foram mais eficazes em aumentar esse parâmetro em comparação aos outros tratamentos. Não houve diferença entre os grupos em relação à capacidade de síntese de PGE2 e à fosforilação de proteínas intracelulares. A partir dos resultados obtidos é possível concluir que os ACR contribuem significativamente para a viabilidade celular, bem como para a síntese de mediadores pró e anti-inflamatórios, sendo que o protocolo de suplementação se apresenta como fator determinante para obtenção desses resultados. Apesar da literatura científica atribuir grande parte dos efeitos imunomodulatórios à leucina, os resultados obtidos nesse estudo atribuem relevante potencial imunomodulador à isoleucina, abrindo espaço para um importante tema de estudo

Branched chain amino acids (BCAA) are considered indispensable, since they cannot be endogenously synthesized, being easily obtained by diet. However, in certain clinical conditions, both the intake and absorption of these amino acids may be compromised, leading to the hypercatabolic state and impairing the immune function. The immunomodulatory role of BCAA has been associated with the nitrogen balance improvement and the increase of production and proliferation of immune cells, as well as the synthesis of inflammatory mediators. However, the mechanisms by which BCAA modulate the immune system have not yet been completely elucidated. In this sense, this study aimed to evaluate the effects of BCAA supplementation on intracellular mechanisms and inflammatory parameters in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Cell cultures were distributed into five groups: CTL - without ACR supplementation; LEU - supplemented with leucine (2 mmol/L); ISO - supplemented with isoleucine (2mmol / L); VAL - supplemented with valine (2 mmol/L) and LIV - supplemented with leucine (2 mmol/L), isoleucine (2 mmol/L) and valine (2 mmol/L). The inflammatory state was induced by the addition of LPS (1 µg/ml) to the culture medium, following four treatment protocols: PT - pre-treatment; TA - acute treatment; TC - chronic treatment and TT - late treatment. The cell viability assay was performed by the MTT test and the nitric oxide (NO) dosage by the Griess reaction. Pro- and anti-inflammatory cytokines, and prostaglandin E2 (PGE2) were analyzed by ELISA. For the evaluation of the molecular parameters, the western blotting method was used. There was an increase in cell viability in all supplemented groups in relation to the control group in the TA, TC and TT treatments. Regarding NO synthesis, BCAA supplementation was able to increase NO production in three of the four proposed treatments (PT, TA and TC). In relation to the production of pro- and anti-inflammatory cytokines, PT and CT were more effective in increasing this parameter, compared to the other treatments. There was no difference between groups in relation to PGE2 production and intracellular protein phosphorylation. From the obtained results it is possible to conclude that the BCAA significantly contributed to the cell viability, as well as, for the production of pro and anti-inflammatory mediators, and the supplementation protocol presents as determinant factor to obtain these results. Although the scientific literature attributed a large part of the immunomodulatory effects to leucine, the results obtained in this study attribute relevant immunomodulatory potential to isoleucine, opening space for an important study topic

Risk Assessment of "Other Substances" – L-leucine, L-isoleucine and L-valine, the Branched Chain Amino Acids (BCAA)

The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. The risk assessments are the scientific basis for NFSA in its efforts to regulate the use of "other substances" to food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/or physiological effect. It is added mainly to food supplements, but also to energy drinks and other foods. VKM has not in this series of risk assessments of "other substances" evaluated any claimed beneficial effects from these substances, only possible adverse effects. The present report is a risk assessment of L-leucine, L-isoleucine and L-valine and it is based on previous risk assessments and articles retrieved from a literature search. In this report Lleucine, L-isoleucine and L-valine may occasionally be termed merely leucine, isoleucine or valine. L-leucine, L-isoleucine and L-valine are essential amino acids. L-leucine, L-isoleucine and Lvaline are commonly known as Branched Chain Amino Acids (BCAAs), and are found in food items containing proteins and in particular, in protein-rich foods such as dairy products, meats, eggs, nuts, whole grains, seeds, avocadoes and edible seaweed. According to information from NFSA, L-leucine, L-isoleucine and L-valine are ingredients in food supplements sold in Norway. NFSA has requested a risk assessment of the following doses of L-leucine, L-isoleucine and L-valine in food supplements for adults, adolescents and children 10 years and above: L-leucine: 2500, 3000, 4000, 5000 and 5250 mg/day, Lisoleucine: 1500, 1750, 2000 and 2500 mg/day and L-valine: 1500, 1750, 2000, 2250 and 2500 mg/day. Usual dietary intakes of these amino acids in Norway are not known. Based on data from the 1988–1994 NHANES III, mean daily intakes in adults of leucine, isoleucine and valine from food and supplements are 6.1, 3.6 and 4.0 g/day, respectively (IOM, 2005). Most studies on BCAAs have focused on the three amino acids taken as single amino acids or together combined in food supplements. It has been shown that BCAAs are not metabolized in the liver as is common for most other amino acids but taken up by most peripheral tissues (in particular muscle) where they are either used in protein synthesis or as precursors for nitrogen and/or a number of carbon containing molecules. There is a lack of relevant well-designed supplementation studies with L-leucine, L-isoleucine and L-valine in humans designed to address adverse effects and dose-response relationships as primary outcome. However, daily doses of as much as 30 g BCAA per day given to athletes have been investigated and reported to improve performance. In these reports adverse effects were not addressed and not reported. L-leucine has been administered orally in single doses for one day of up to 50 g without showing any adverse effects. There are no published studies on the effects of longitudinal supplementation with either L-isoleucine or L-valine. Thus, there are no published studies that can be used for suggesting a "value for comparison", and there is no scientific data in the literature suitable for assessing the specific doses in the terms of reference. WHO (2007) recommendations for BCAAs are: Leucine 2730 mg/day, isoleucine 1400 mg/day and valine 1820 mg/day. For a 70 kg person, this corresponds to 39 mg leucine/kg body weight (bw) per day, 20 mg isoleucine/kg bw per day and 26 mg valine/kg bw per day. The acute upper tolerable metabolic limit of L-leucine for men between 20 and 35 years was determined by administration of single doses of 550-700 mg/kg bw over one day. This corresponded to 39 to 50 g/day for a person of 70 kg. Furthermore, based on several studies investigating L-leucine, L-isoleucine and L-valine supplemented as single doses ranging from 10 to 30 g/day without any reported adverse effects. The uncertainties for this consideration are described in chapter 5. VKM concludes that: Due to lack of studies addressing adverse effects for the specified doses 2500, 3000, 4000, 5000 and 5250 mg/day L-leucine, 1500, 1750, 2000 and 2500 mg/day L-isoleucine and 1500, 1750, 2000, 2250 and 2500 mg/day L-valine in food supplements, no conclusions can be made for adults (≥ 18 years), adolescents (≥ 10 and < 18 years) or children (< 10 years).

Action of leucine in heart hypertrophy induced by thyroid hormone in rats / Ação da leucina na hipertrofia cardíaca induzida pelo hormônio tireoidiano em ratos

Leucine is a regulator of protein metabolism in vivo, but there is little information regarding its effect on hyperthyroidism-induced cardiac hypertrophy. This study aimed to verify the action of leucine in heart hypertrophy using an experimental model of hyperthyroidism in rats. A total of 40 Wistar rats were used and allocated randomly into four groups: control (C), hormone (H), leucine (L) and hormone plus leucine (HL). Hyperthyroidism was induced by administering daily by gavage 20 µg of levothyroxine sodium in aqueous suspension per 100 g of body weight, and leucine was supplemented by adding 5% of the amino acid to conventional food. After 28 days, the heart was removed and weighed; the left ventricle was separated along with the interventricular septum and weighed. Histological slides were made from the left ventricle and stained with hematoxylin-eosin to measure the transverse diameter of cardiomyocytes. Two-way analysis of variance (ANOVA) and Tukey post-test were used and significance level set at 5%. There was a significant increase in the absolute heart weight, the left ventricular weight and cardiomyocyte diameter in rats of the H group compared to the other groups. The addition of leucine inhibited heart hypertrophy. Levothyroxine sodium-induced cardiac hypertrophy in Wistar rats is inhibited by leucine.

A leucina é um regulador do metabolismo proteico in vivo, e existem poucas informações referentes à sua ação na hipertrofia cardíaca induzida pelo hipertireoidismo. O estudo teve por objetivo verificar a ação da leucina na hipertrofia cardíaca de ratos Wistar em um modelo experimental de hipertireoidismo. Foram utilizados 40 animais, alocados ao acaso em quatro grupos, sendo: grupo controle (C), grupo hormônio (H), grupo leucina (L) e grupo hormônio + leucina (HL). O hipertireoidismo foi induzido administrando-se, diariamente, 20µg/100 gramas de levotiroxina sódica em suspensão aquosa, por gavagem e a leucina foi suplementada adicionando-se 5% do aminoácido à ração convencional. Ao final do período experimental, o coração foi removido e pesado. Foi separado o ventrículo esquerdo juntamente com o septo interventricular e pesado. Foram feitas lâminas histológicas a partir do ventrículo esquerdo, coradas com hematoxilina-eosina, para a medida do diâmetro transversal dos cardiomiócitos. Foi utilizada a análise de variância (ANOVA) de duas vias e pós-teste de Tukey e adotado um P<0,05. Houve aumento significante para o peso do coração, peso do ventrículo esquerdo e diâmetro dos cardiomiócitos no grupo H em relação aos demais grupos. A adição de leucina inibe a hipertrofia. A hipertrofia cardíaca induzida em ratos Wistar pela levotiroxina sódica é inibida pela leucina.

Consumo de aminoácido de cadeia ramificada na esclerose lateral amiotrófica: suplemento proteico ou substância neurotóxica? / Branched-chain amino acid consumption in amyotrophic lateral sclerosis: protein supplement or neurotoxic substance?

Estudos demonstraram efeito positivo principalmente no ganho ponderalem pacientes com esclerose lateral amiotrófica (ELA), suplementadoscom aminoácidos de cadeia ramificada (AACR). Achados recentes têm mostrado que o consumo excessivo e crônico de AACR pode contribuir para a progressão da doença, provavelmente devido a estes serem precursores do glutamato. O objetivo deste estudo foi avaliar a evidência acerca da utilização dos AACR por pacientes com ELA, a fim de elucidar questões pertinentes a sua ingestão. Foi feita busca em base de dados de artigos científicos relacionados ao consumo de AACR na ELA, no período de 1988 a 2013. Foram encontrados seis artigos relacionados ao consumo de AACR por pacientes com ELA. Desses, um referiu melhora da força, enquanto os outros relataram ganho ponderal ou não mostraram resultados significativosem relação aos desfechos. Além disso, foi possível observar uma estreita relação entre o consumo excessivo e crônico dos AACR com o agravamento da doença. À luz dos conhecimentos ora disponíveis, a suplementação com AACR não é recomendada devido aos possíveis efeitos nocivos. O consumo adequado de alimentos proteicos, fontes desses aminoácidos, deve ser utilizado pelos pacientes, respeitando as recomendações estabelecidas. No entanto, estudos adicionais devem ser desenvolvidos em virtude do escasso número de publicações disponíveis.

Studies have shown positive effect mainly in weight gain inpatients with amyotrophic lateral sclerosis (ALS) supplemented with branched chain amino acids (BCAA). However, recent studies have shown that excessive and chronic intake has contributed to the worsening of the disease progression, probably because the amino acids are glutamate precursors. The objective of this study was to assess the evidence about the use of BCAA by patients with ALS, with the aim to clarify pertinent issues for its intake. A search was conducted in data bases for scientific papers related to the intake of BCAA in ALS, between 1988 and 2013. For these review six articles related to the use of BCAA in ALS were found. Of these, one described strength improvement, while the remaining reported weight gain or no significant effects in relation to the outcome. Additionally, it waspossible to observe a close relationship between the excessive and chronic BCAA intake with the worsening of the disease. Considering the presente day available knowledge BCAA supplementation should not be indicated due to the possible harmful effect. The intake of appropriated protein foods should be consumed by these patients, respecting the suggested recommendation. However, more studies are necessary due to the scarce papers in this area.

Effects of Branched-Chain Amino Acid Supplementation on Blood Glucose,Alanine and Lactate of Rowers after Different Loads of Exercise / 中国运动医学杂志

Objective This study was to investigate the effects of branched-chain amino acid (BCAA) supplementation on the metabolism of glucose and gluconeogenesis. Methods 20 rowers were randomly assigned to supplemental group and control group. During 4 weeks of training, all athletes followed the same training program. After 4 weeks, tests were done on a rowing ergometer, which included an incremental test for 4 mmol/L lactate anaerobic threshold and 2km, 5km maximum intensity exercise. Blood samples were taken prior to, immediately post and 30min post exercise. Results The results showed that serum glucose, alanine values had no significant difference between BCAA group and control group in anaerobic threshold test. In 2km and 5km rowing ergometer exercise, serum glucose values in BCAA group were significant decreased immediately post exercise, but the values in control group were significant decreased both immediately post exercise and 30min post exercise. Serum alanine values in BCAA group were significant increased both immediately post exercise and 30min post exercise, but the values in control group were significant decreased immediately post exercise. Lactate concentrations increased in BCAA supplementation group and were significantly lower (P